Literature DB >> 30393606

Identification of a novel therapeutic target in driver-negative non-small cell lung cancer.

Motonobu Saito1,2, Koji Kono1, Takashi Kohno2.   

Abstract

Entities:  

Year:  2018        PMID: 30393606      PMCID: PMC6193893          DOI: 10.21037/tlcr.2018.08.10

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


× No keyword cloud information.
  21 in total

Review 1.  Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Authors:  Filip Janku; David J Stewart; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

2.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

4.  Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Authors:  Alexander Drilon; Lu Wang; Adnan Hasanovic; Yoshiyuki Suehara; Doron Lipson; Phil Stephens; Jeffrey Ross; Vincent Miller; Michelle Ginsberg; Maureen F Zakowski; Mark G Kris; Marc Ladanyi; Naiyer Rizvi
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

5.  The genomic and epigenomic landscape in thymic carcinoma.

Authors:  Motonobu Saito; Yutaka Fujiwara; Tetsuhiko Asao; Takayuki Honda; Yoko Shimada; Yae Kanai; Koji Tsuta; Koji Kono; Shunichi Watanabe; Yuichiro Ohe; Takashi Kohno
Journal:  Carcinogenesis       Date:  2017-10-26       Impact factor: 4.944

6.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

7.  A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.

Authors:  Motonobu Saito; Teruhide Ishigame; Koji Tsuta; Kensuke Kumamoto; Toshio Imai; Takashi Kohno
Journal:  Carcinogenesis       Date:  2014-07-26       Impact factor: 4.944

8.  A secondary RET mutation in the activation loop conferring resistance to vandetanib.

Authors:  Takashi Nakaoku; Takashi Kohno; Mitsugu Araki; Seiji Niho; Rakhee Chauhan; Phillip P Knowles; Katsuya Tsuchihara; Shingo Matsumoto; Yoko Shimada; Sachiyo Mimaki; Genichiro Ishii; Hitoshi Ichikawa; Satoru Nagatoishi; Kouhei Tsumoto; Yasushi Okuno; Kiyotaka Yoh; Neil Q McDonald; Koichi Goto
Journal:  Nat Commun       Date:  2018-02-12       Impact factor: 14.919

9.  Selective RET kinase inhibition for patients with RET-altered cancers.

Authors:  V Subbiah; V Velcheti; B B Tuch; K Ebata; N L Busaidy; M E Cabanillas; L J Wirth; S Stock; S Smith; V Lauriault; S Corsi-Travali; D Henry; M Burkard; R Hamor; K Bouhana; S Winski; R D Wallace; D Hartley; S Rhodes; M Reddy; B J Brandhuber; S Andrews; S M Rothenberg; A Drilon
Journal:  Ann Oncol       Date:  2018-08-01       Impact factor: 32.976

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.